Financials

View key financial information for Prestige Biopharma.

Consolidated Statement of Comprehensive Income

(Unit: USD 1K)
11th Fiscal Year (Q3) 10th Fiscal Year 9th Fiscal Year
July 1, 2025 – March 31, 2026 July 1, 2024 – June 30, 2025 July 1, 2023 – June 30, 2024
Revenue 7,460 10,215 517
Cost of sales 17,195 19,226 8,706
Gross Profit (9,736) (9,011) (8,189)
Selling and administrative expenses 39,359 39,015 38,926
Operating Income (49,095) (48,025) (47,115)
Net Income 2,974 (41,348)

Consolidated Statement of Financial Position

(Unit: USD 1K)
11th Fiscal Year (Q3) 10th Fiscal Year 9th Fiscal Year
March 31, 2026 June 30, 2025 June 30, 2024
Total Assets 506,453 549,730 512,324
Current Assets 70,346 154,824 180,213
Non-current Assets 436,108 394,906 332,111
Total Liabilities 139,942 174,980 141,246
Current Liabilities 82,684 121,883 104,994
Non-current liabilities 57,259 53,098 36,252
Total stockholders’ equity 366,511 374,750 371,078
Share Capital 525,728 525,727 525,727
Capital Surplus (23,302) (23,301) 5,662
Other Capital 8,393 7,904 7,569
Accumulated Other Comprehensive Income 32,145 (11,007) (10,679)
Retained Earnings (230,200) (196,307) (212,207)
Non-controlling Interest 53,748 71,735 55,006
Total Equity 506,453 549,730 512,324